SO how did this even happen
At the time the study was under way, consumers were flocking to telehealth providers and compounders that sold less-expensive knockoff versions of GLP-1 weight-loss drugs
Our goal is to learn whether the study medicines are safe and effective treatment options for people living with overweight or obesity and other weight-related conditions
Moreover, the observation that adding GLP-1MK-801 treatment on top of semaglutide leads to an additional weight loss of 7% in mice that have reached a weight loss plateau with semaglutide provides additional support for integrating NMDA receptor antagonism in next-generation weight loss therapeutics
More serious potential risks include gallbladder disease and acute pancreatitis (seek urgent medical attention for severe, persistent abdominal pain radiating to the back)
You're communicating asynchronously - you send a message, a clinician reviews it, and you get a response